hyperaldosteronism
HYPERALDOSTERONISM
Hyperaldosteronism is a group of disorders in which aldosterone production is inappropriately high, relatively autonomous & non-suppressible by sodium loading.
Signs & symptoms are nonspecific.
Symptoms are caused by hypertension (eg headache), hypokalemia (eg polyuria, nocturia, muscle cramps & weakness, tetany, paralysis, etc) & metabolic alkalosis.

Hyperaldosteronism References

  1. Foo R, O'Shaughnessy KM, Brown MJ. Hyperaldosteronism: recent concepts, diagnosis, and management. Postgrad Med J. 2001 Oct;77(912):639-644. PMID: 11571370
  2. Lim PO, Rodgers P, Cardale K, et al. Potentially high prevalence of primary aldosteronism in primary-care population. Lancet. 1999 Jan;353(9146):40. PMID: 10023956
  3. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008 Sep;93(9):3266-3281. PMID: 18552288
  4. Ganguly A. Primary aldosteronism. N Engl J Med. 1998 Dec;339(25):1828-1834. PMID: 9854120
  5. Gallay BJ, Ahmad S, Xu L, et al. Screening of primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio [abstract]. Am J Kidney Dis. 2001 Apr;37(4):699-705. PMID: 11273868
  6. Schwartz GL, Chapman AB, Boerwinkle E, et al. Screening of primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem. 2002 Nov;48(11):1919-1923. PMID: 12406976
  7. Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment of strategies [review]. Nat Clin Pract Nephrol. 2006 Apr;2(4):198-208. PMID: 16932426
  8. Young WF Jr. Minireview: primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology. 2003 Jun;144(6):2208-2213. PMID: 12746276
  9. Torre JJ, Bloomgarden ZT, Dickey RA, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension. Endocr Pract. 2006 Mar;12(2):193-222. PMID: 16718944
  10. Stewart PM. Adrenal cortex: renin-angiotensin system in adrenocortical hypertension. Comprehensive clinical endocrinology. 3rd ed. London: Mosby; 2002
  11. Young WF Jr. Endocrine hypertension. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. William's Textbook of Endocrinology. 11th ed. Philadelphia: Saunders, an imprint of Elsevier; 2008
  12. MedWormhttp://www.medworm.com/rss/index.php/Endocrinology/15/http://www.medworm.com/rss/medicalfeeds/specialities/Endocrinology.xml
  13. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  14. Young, WF Jr, Kaplan NM. Treatment of primary aldosteronism. UptoDate. http://www.uptodate.com/contents/treatment-of-primary-aldosteronism. 2014 Apr.
  15. Wayne MA. Aldosteronism. ARUP Consult website. http://www.arupconsult.com/Algorithms/Hyperaldosteronism.pdf. 22 Jun 2012. Accessed 09 Mar 2015.
  16. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-1916. doi: 10.1210/jc.2015-4061. PMID: 26934393
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Cycling was associated with reduced risk for both all-cause and cardiovascular (CV) mortality in people with diabetes, according to a study presented at EASD 2020 Meeting — suggesting that cycling could be encouraged as an activity to prevent deaths in this population who are known to have a higher mortality risk than the general public.
Elaine Soliven, 5 days ago

Higher levels of exercise appear to be associated with a lower risk of all-cause mortality in adults with type 2 diabetes (T2D) compared with no exercise at all, according to a study presented at EASD 2020.

Pearl Toh, 09 Oct 2020
SGLT-2 inhibitors may confer more cardiovascular (CV) protective benefits than GLP-1 RAs in patients with type 2 diabetes (T2D), according to a real-world study presented at the EASD 2020 virtual Congress.
Elvira Manzano, 07 Oct 2020
Exendin-4 imaging targeting GLP-1* receptor (GLP-1R) ably detects residual, dysfunctional pancreatic beta cells in individuals with long-standing type 1 diabetes (T1D), according to a study presented at EASD 2020. This breakthrough brings research closer to the possibility of restoring insulin-producing cells depleted in T1D.